Insulet Corporation announced the appointment of Flavia Pease as the new Chief Financial Officer, succeeding Ana Maria Chadwick.
Flavia Pease brings extensive global healthcare and medical technology industry experience to her new role, following her successful career at Charles River Laboratories and Johnson & Johnson.
The company expects to exceed its third quarter 2025 revenue growth guidance, driven by strong new customer starts in both U.S. and international markets.
Appointment of Flavia Pease
Flavia Pease will succeed Ana Maria Chadwick as the Executive Vice President and Chief Financial Officer of Insulet Corporation, effective September 30, 2025.
Financial Performance Expectations
Insulet Corporation anticipates surpassing its third quarter 2025 total revenue growth guidance due to strong customer starts in domestic and international markets.
Previous Experience of Flavia Pease
Flavia Pease has a rich background in scaling businesses, leading global operations, and driving growth in complex healthcare markets, as evidenced by her roles at Charles River Laboratories and Johnson & Johnson.
- Flavia Pease's appointment is expected to further strengthen Insulet Corporation's financial leadership and guide the company towards patient-centric growth.
- The company's positive revenue outlook for the third quarter of 2025 reflects strong market demand for its Omnipod products in the U.S. and global markets.
With Flavia Pease stepping into the role of Chief Financial Officer, Insulet Corporation is poised for continued success and growth in the healthcare industry.